UCSF researchers have identified a new "feed-forward" pathway linking estrogen receptors in the membrane of the uterus to a process that increases local estrogen levels and promotes cell growth.
Get the full story...
Breast cancer cells that express estrogen receptor (ER) can be treated with tamoxifen only as long as they remain sensitive to the drug. Resistance to tamoxifen is a common problem in breast cancer treatment, but researchers are identifying the factors that influence sensitivity versus resistance.
Get the full story...
For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates, according to a new study Published in the March 15, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
Read the full story
In the clinical practice setting almost a quarter of women treated for breast cancer stop tamoxifen within one year, a rate twice as high as indicated by previous studies. The new study, published in the March 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, says early termination of this highly effective breast cancer drug may negatively affect treatment efficacy.
Read the full story
Radiation therapy after lumpectomy and five years of treatment with the drug tamoxifen can dramatically reduce the risk of both cancer recurrence and new tumors in older women with early breast cancer, according to researchers from Wake Forest University School of Medicine and colleagues.
Read the full story
Treatment with Aromasin after five years of tamoxifen results in significant improvement in relapse-free survival
Read the full story
